And to feel the full effect, your body must first have a B12 deficiency
Both are overwhelmingly preclinical for recovery
Where retatrutide likely falls Based on the pattern that greater weight loss correlates with greater hair shedding risk, and given that retatrutide produces the most aggressive weight loss of any medication in the class, the logical prediction is that retatrutide will show a hair loss incidence somewhere at or above tirzepatide levels (5% or higher) in large-scale clinical trials
More specifically, it asked FDA to clarify that identification thresholds may be consistent with ICH Q3A(R2) and ICH Q3B(R2) thresholds or with an otherwise justified limit

Potential benefits of using GLP-1 receptor agonists after gastric sleeve surgery include: Enhanced weight loss : Observational studies suggest post-bariatric patients using GLP-1 receptor agonists may achieve additional weight reduction, typically around 510% of body weight, though individual responses vary considerably Improved glycaemic control : Particularly beneficial for patients with type 2 diabetes or prediabetes, as GLP-1 agonists enhance insulin secretion and reduce blood glucose levels Reduced appetite : These medications can help patients who struggle with persistent hunger despite surgical intervention Cardiovascular benefits : Semaglutide has demonstrated cardiovascular risk reduction in people with established cardiovascular disease, which may benefit eligible post-bariatric patients with this specific risk profile Maintenance of weight loss : May help prevent weight regain during the critical maintenance phase Potential risks and considerations include: Gastrointestinal side effects : Nausea, vomiting, diarrhoea, and constipation are common, particularly during dose escalation
